Kenvue Inc. (NYSE:KVUE) Shares Sold by South Dakota Investment Council

South Dakota Investment Council lowered its position in Kenvue Inc. (NYSE:KVUE) by 17.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 335,366 shares of the company’s stock after selling 69,565 shares during the quarter. South Dakota Investment Council’s holdings in Kenvue were worth $7,160,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank lifted its holdings in Kenvue by 26.5% in the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after buying an additional 871 shares in the last quarter. ING Groep NV raised its stake in shares of Kenvue by 23.6% in the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock valued at $82,727,000 after purchasing an additional 681,954 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock valued at $15,846,000 after purchasing an additional 21,222 shares in the last quarter. Alberta Investment Management Corp raised its stake in shares of Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock valued at $12,445,000 after purchasing an additional 109,700 shares in the last quarter. Finally, Empower Advisory Group LLC acquired a new stake in shares of Kenvue in the 4th quarter valued at about $48,252,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE KVUE opened at $23.31 on Friday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $44.68 billion, a price-to-earnings ratio of 43.97, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. The company has a 50-day moving average price of $21.31 and a two-hundred day moving average price of $22.18.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Barclays cut their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Canaccord Genuity Group cut their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Citigroup dropped their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.